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Abstract 
Surgical site infection (SSI) occurs when a wound created as part of a surgical procedure 
becomes infected. SSI is one of the most common healthcare associated infections and 
occurs in approximately  5% of patients undergoing a surgical procedure. SSI may lead to 
patients suffering  considerable morbidity or mortality and have significant cost 
implications. The aetiology involves the interplay of host, environmental and pathogen 
factors all of which should be addressed in seeking to reduce the risk of developing an 
infection. The presence of prosthetic material reduces the number of bacteria necessary for 
an infection to develop and can give rise to treatment and diagnostic difficulties. The 
responsible organisms are most commonly Staph aureus and Staph epidermidis. Diagnosis is 
frequently problematic and antibiotic treatment alone is often ineffective due to biofilm 
formation necessitating removal of prosthesis in many cases. Prevention of infection is by 
far the most important aspect of prosthetic implant surgery. Patient optimisation is equally 
important as the cutting edge research into biological prostheses in reducing the incidence 
of prosthetic infection in future practice.  
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Introduction 
The Centre for Disease Control defines a Surgical Site Infection (SSI) as an infection within 30 
days of an operation or up to one year if a surgical prosthesis is implanted during the 
procedure. Surgical site infections reportedly occur in 5% of patients leading to considerable 
morbidity and over a third of post-operative deaths are related, at least in part, to an SSI [1]. 
However it has been suggested that when close post discharge surveillance is undertaken, 
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SSI complicate 10-20% of surgical procedures indicating an underestimation of the incidence 
within all surgical specialties[2].  
A surgical prosthesis is defined as ‘artificial material which is used to replace missing part or 
parts after surgical intervention’ and includes vascular grafts, orthopaedic appliances and 
synthetic mesh. Careful consideration must be given to the need for insertion of prosthetic 
material as it acts as a foreign body within the surgical wound and studies have previously 
demonstrated a logarithmic decrease in the number of bacteria required to cause an SSI in 
the presence of a prosthesis [3].  
The actual risk of developing a SSI in the presence of a surgical prosthesis is unknown, but 
approximately half of healthcare associated infections in the US are reportedly related to 
surgery involving prosthetic material. Current literature quotes an SSI incidence of between 
0.2 and 6% in vascular grafts[4], 0.3- 1.9% in knee and hip arthroplasties[5] and 
approximately 1.25% in cardiac device[6]. 
 
Factors influencing prosthetic infection  
Many factors influence the healing of surgical wounds and hence the potential for and 
incidence of SSI and prosthetic implant infection. Patient factors known to increase the 
incidence of SSI are summarised in table 1.   
Table 1: Risk factors for the development of surgical site infections 
 
Patient Risk Factors  
Age Peak at 65 yrs due to ↑ co-morbidities 
Smoking Platelet aggregation and ↓ oxygen carriage 
Nutrition Hypoalbuminaemia <30mg/dl is independent risk factor 
for SSI 
Obesity ↓ tissue oxygen tension levels 
Diabetes ↓ tissue perfusion and impaired cellular immune 
response 
Corticosteroids ↓ vascular permeability and impaired cellular immune 
response 
Burns/trauma Impaired cellular immune response 
Neoplasia/ chemo-radiotherapy Impaired cellular immune response 
 
 
Risk stratification 
The National Academy of Sciences classification allocates all surgical wounds to one of 4 
categories - clean, clean contaminated, contaminated and dirty. SSI incidence varies from 
<2% for clean wounds compared to up to 40% for dirty wounds. 
 
The National Nosocomial Infections Surveillance System risk index for the development of 
SSI comprises a 0-3 score using the following three risk factors. 
  
a) An pre-operative assessment score of 3, 4 or 5 in the five category American Society of 
Anesthesiologists’ system 
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b) Wound classified as contaminated or dirty  
c) Procedure lasting more than a specific period of time (‘T hours’), where T is the 75th 
percentile of the duration of the surgery being performed surgery.  
Pathogenesis  
When a prosthesis is implanted it is immediately surrounded by a pool of blood and 
inflammatory fluid. Initial fibrinogen adherence facilitates formation of a proteinaceous 
layer consisting of platelets and red blood cells.  Subsequent white blood cell adherence to 
this layer leads to bacterial adhesion and the possibility of prosthetic infection[7]. Different 
prostheses display differing critical surface tensions. A higher surface tension results in  
greater adherence of fibrinogen and platelets and the subsequent risk of bacterial 
colonisation and prosthetic infection. Coagulase negative staphylococci, are the most 
common causative pathogens responsible for ‘clean’ implant surgery. This is because they 
possess surface proteins which have adhesive properties and facilitate the initial 
colonisation of prostheses [8].   
 
Non-haemolytic S. epidermidis has been determined to be the single most common 
pathogen in the development of prosthesis material infections[9]. This is due to the ability 
to produce an exopolysaccharide (slime) which coats the prosthesis and in doing so 
facilitates further bacterial adhesion leading to formation of a biofilm[10]. This biofilm has 
been shown to promote the adherence of other bacteria to a prosthesis and also to render 
the micro-organisms less susceptible to circulating antimicrobials. The biofilm decreases 
chemotaxis and opsonization of neutrophil granulocytes, increases degranulation, and 
blocks antibiotic penetration into the bacterial cell[10]. The nature of the biofilm can make 
isolation of the bacteria on blood culture difficult and strains are often only isolated after 
removal and culture of the prosthetic material. This hampers diagnosis and is compounded 
by the long latent period and indolent nature of S. epidermidis infection.  
 
Staphylococcus aureus (S. aureus) is a gram-positive, coagulase positive coccus. Many 
isolates exist, each have their own virulence factors and hence each responsible for the 
development of differing infections. Along with factors allowing adherence to epithelial and 
endothelial lined surfaces, most strains also possess a fibronectin and fibrinogen binding 
protein promoting adherence to blood clots and traumatised tissues. S. aureus accounts for 
30% of all soft tissue SSI and thus is a frequent isolate in prosthetic infections [11].  
Methicillin Resistant S. aureus (MRSA) is a strain of S. aureus which has developed 
resistance to the actions of methicillin and other β-lactam antibiotics. Almost half (49.2%) of 
prosthetic infections due to s. aureus are due to MRSA strains [11]. Some S. aureus strains 
have even developed resistance to vancomycin and are termed VRSA (Vancomycin resistant 
S. aureus). 
 
Organisms such Streptococci, diphtheroids and enterococci each account for approximately 
10% of ?prosthetic infections, whilst gram-negative cases are much less common. 
Anaerobes are usually only found as components of a polymicrobial infection. 
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 Prevention 
Interest in SSI and prosthetic infection has increased in recent years and a growing evidence 
base is available for interventions which may impact upon the incidence of infection 
following surgery. However, seemingly obvious questions such as the best methods for 
reducing bacterial load in the area of the incision or timing of administering antibiotics are 
still to be conclusively answered. Prevention strategies are summarised in Table 2.  
 Table 2. Strategies to prevent surgical site infections  
Pre operative  
MRSA screening and 
decontamination 
Shown to reduce incidence of MRSA SSI  
 
Hair removal  Removal does not reduce infection – if necessary  
clippers reduce SSI incidence compared to shaving 
Patient preoperative showering: 
 
Known reduction in skin bioburden but inconclusive  
evidence of reduction in SSI 
Antibiotics Prophylactic antibiotics should be given for implant  
surgery during anaesthetic induction (earlier if 
tourniquet to be used– post op regimes contentious 
Inter operative  
Skin prep in theatre: 
 
Current evidence inconclusive for any single best agent 
– alcohol likely to play an important role in efficacy  
Adhesive occlusive drapes Iodine impregnated drapes may reduce SSI – non 
impregnated drapes may actually increase SSI incidence 
Diathermy skin incision No evidence of reduced SSI compared to scalpel incision 
Procedure length ↑ duration of procedure is directly linked to ↑ risk of 
SSI 
Wound closure technique Subcuticular suture allows greatest perfusion of skin 
edges but no evidence of reduced SSI 
Antimicrobial –coated sutures Triclosan-coated sutures appear to reduce incidence of 
SSI compared to conventional sutures 
Theatre discipline Staff numbers, number of door openings, noise levels in 
theatre all linked to increased SSI 
Oxygen tension ↑ concentrations of inspired oxygen result in ↓ SSI 
rates 
Hypothermia ↑ O2 demand and acidosis causing poor perfusion of 
end organs  
 
 
Clinical Presentation  
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An SSI may present at any time up to a year following prosthetic implant surgery, infections 
of implants after this time are considered to be due to a cause not related to the implant 
procedure (eg Haematogenous spread). Early prosthetic infections occurring within 30 days 
of a surgical procedure, frequently present with pain, fever, leucocytosis, bacteraemia and 
cellulitis. In some instances there may be abscess formation or a sinus tract discharging pus. 
Intermediate infections may occur between one and three months following surgery with a 
similar presentation to early infections. Late infections present more than three months 
post- operatively. They are often indolent in nature and are frequently caused by less 
virulent bacterial strains often presenting with a continually discharging sinus but no clinical 
signs of sepsis and often negative cultures.  
 
 
Orthopaedic 
Orthopaedic prosthetic infections may have a delayed presentation when less virulent 
organisms are responsible and diagnoses may be more problematic. Symptoms such as 
persistent joint pain, deterioration in function and occasionally loosening of the prosthesis 
may be present. Differentiating such chronic infections from aseptic failure or loosening is 
difficult.  
 
Vascular 
The presentation of vascular graft infections depends on the anatomical position of the graft 
and endovascular procedures have the same incidence of prosthetic infection as open 
implant procedures.  Vascular grafts infections may present with chronic or acute pain and 
may be complicated by fistula or pseudo-aneurysm formation, bleeding at the anastomotic 
site, thrombosis of the graft or peripheral embolisation. Occasionally osteomyelitis or non-
healing ulcers may develop in tissues distal to the grafts. 
 
Cardiac 
Infections related to cardiac implantable devices can be divided into two categories: pocket 
infections (infection in the subcutaneous device pocket or the subcutaneous leads) and  
deeper infections (involving the trans-venous portions of the leads and/ or endovascular 
infection such as endocarditis). Deeper infections often give rise to late presentations and 
may feature a persistent or relapsing bacteraemia without obvious source or occasionally 
distal or pulmonary emboli.  
 
 
Diagnosis 
 
Timely diagnosis of prosthetic implant infections is crucial in preventing morbidity and 
mortality. Accuracy of diagnosis is particularly important in avoiding significant insult from 
the implant removal and or revision surgery that such infections necessitate. The presence 
of a surgical prosthesis should provoke a high level of suspicion in the clinician assessing any 
patient with ongoing symptoms relating to surgical sites or infective symptoms of unknown 
origin.  Initial assessment should include blood sampling for inflammatory markers though a 
leucocytosis and elevated CRP would be expected in the immediate post-operative period, 
and serial measures to detect a trend are more helpful than solitary results.     
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Microbiological culture specimens must be sent from all relevant sites for gram stain and 
culture. Prior antibiotic administration may result in a failure to demonstrate a pathogen in 
culture specimens making it imperative that, where possible, cultures should be obtained 
before commencing treatment.  Blood cultures should be obtained from several sites 
especially if haematogenous spread is a possibility. 
 
Surface swabs from skin around incision sites are often difficult to interpret due to 
colonising organisms acting as sample contaminants. Fine needle aspiration of surgical 
wound cellulitis has been advocated as more likely to identify a single causative organism 
when compared to surface skin swabs [12] though this is not common practice in most units 
to date. Cultures of aspirated peri-prosthetic fluid collection or synovial fluid remain the 
most reliable methods of diagnosis. Peri-prosthetic tissue biopsies may also be considered in 
some cases. 
 
In cases where drained collections reveal white cells but no pathogens, S. epidermidis 
should be considered. 
 
Diagnostic Imaging 
 
The use of imaging for the diagnosis of prosthetic infections must be tailored to the patient 
and the prosthesis type as each modality has its sensitivities and specificities as well as 
advantages and disadvantages. 
 
X-rays have little role in the diagnosis of prosthetic infections with the exception of 
orthopaedic implants (Fig 1). Joint loosening may be diagnosed on plain radiography but 
serial examinations may be required. For more accurate examination of the interface 
between the cement and bone, MRI may be necessary. 
 
Ultrasound (US) 
 US is radiation free but is highly operator dependant and whilst useful in detecting 
complications due to infection (pseudo-aneurysm, peri-prosthetic collection) has a limited 
role in detecting low grade infection of prostheses. US echocardiogram may assist in the 
diagnosis of infective endocarditis of a prosthetic valve by the identification of vegetations, 
thrombus, or a pericardial effusion. Sensitivity for vegetations is higher with trans-
oesophageal (85-90%) rather than trans-thoracic (~75%) echocardiogram[13]. 
 
Computed tomography and Magnetic resonance scanning  
Both are less operator dependant that USS. Scans can be obtained quickly and large areas 
imaged accurately (Fig 2). It has been reported that MRI and CT have comparable 95% 
specificity and 55% sensitivity for prosthetic vascular graft infection. The low sensitivity in 
both cases is due to difficulties differentiating between the normal post operative changes 
of haematoma, but the presence of these signs should be considered abnormal after 6-8 
weeks[14].  
 
The use of CT is limited by stainless steel alloy devices which can result in image artefacts 
which may compromise the value of the scan though artefact is less of a problem with the 
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newer titanium and nitinol implants and stents / grafts. CT does result in a very high 
radiation dose and the requirement for nephrotoxic contrast is relatively contraindicated in 
chronic kidney disease. MRI can only be performed in patients with non-metallic implants or 
those safe for MRI such as titanium or tantalum. The presence of metallic implants or 
prostheses results in significant image artefacts which may render the results un-
interpretable. Equally MRI is contraindicated in patients with cardiac devices such as 
pacemakers. 
 
PET scanning 
Positron emission tomography-computed tomography with 18F-fludeoxyglucose (FDG-PET-
CT) has been widely used in detection of cancer metastatic deposits by highlighting areas of 
enhanced glucose metabolism. Recent advances have suggested this technique to be highly 
sensitive in the detection and exclusion of peri-prosthetic infections in many areas. Very 
promising results for specificity and sensitivity have been reported for aortic and peripheral 
vascular graft infections [15] peri-prosthetic infection in joint replacement surgery[16] and 
prosthetic cardiac valves[17]. 
 
Leucocyte scintigraphty and SPECT-CT 
Tc99m-labelled white cell scans (Fig 3), may prove valuable in cases where there is difficulty 
establishing whether or not the prosthesis is infected. However, despite the very high 
sensitivity (around 100%) for detection of infection, within the first year after surgery there 
is a low specificity (75%) due to remodelling around the prosthesis. 
Further limitations include the production of planar, or two-dimensional images with no 
spatial resolution and limited landmarks for localization .  
 
SPECT-CT combines the use of radioneucleotide tracers with the 3D spatial resolution of CT 
scanning and can address problems due to radiotracers with extensive distribution that 
produce an unfavourable signal “noise” making discrimination of pathology from normal 
activity difficult[18]. The use of SPECT in cancer is well established and it will probably be 
increasingly employed in the investigation of infections in the future a greater experience 
becomes available. Data in prosthetic infection to date is limited to case studies and short 
series.  
 
Management 
Following initial diagnosis the management of prosthetic infections should comprises a 
combination of two or more antibiotics providing a broad activity spectrum at lower 
concentrations to improve efficacy. Treatment should ideally then be rationalised and 
targeted if and when culture and sensitivities confirm the pathogen and preferred antibiotic 
agent.  Unfortunately the prevalence of multi-resistant strains of Coagulase negative 
staphylococci has increased dramatically over that past couple of decades. As with MRSA β 
lactam resistance is the most common. This increase in resistance has emphasised the need 
for the development of new antibiotics such as linezolid and tigecycline.  Antibiotic 
treatment therefore typically has little or no effect against the biofilm on colonised 
prostheses. 
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Management of patients with prosthetic infections often necessitates more aggressive 
surgical treatment. Debridement is often the first step and involves the removal of 
haematoma, devitalised tissue, scar tissue and sinus tracts. Multiple debridements or 
explantation of the infected prosthesis and revision may be necessary. In some situations 
debridement and or explantation is not always feasible given patient co-morbidities and 
surgical risk in which case palliation and long term antibiotic therapy may be most 
appropriate.  
 
Orthopaedic 
Success rates with debribement are reported to be in the region of 60-80% in selected 
patients with prosthetic arthroplasty prostheses[19]. Explantation and revision of an 
infected arthroplasty is the subject of much debate. Many surgeons still favour a 2 stage 
revision involving the use of a temporary antibiotic cement spacer. However comparable 
infection eradication has been reported in a one stage direct exchange procedure, 
predominantly using antibiotic loaded cement. Further studies have shown that antibiotic 
bone compound has better storage capacities and pharmacological kinetics than loaded 
cement and may reduce the re-infection risk. In a limited number of cases where these 
measures fail, arthrodesis or even amputation may be required.   
 
Vascular 
The morbidity and mortality of infected vascular grafts is dependent on the location of the 
graft. The literature reports mortality rates ranging from 6- 75% and an amputation rate of 
21- 70% [20]. Despite high mortality rates associated with resection of infected grafts (25-
35% in aortic grafts) the patient outcomes are thought to be better following surgical as 
opposed to conservative management.   It is therefore clear that management decisions for 
patients with major arterial grafts are problematic. Circumstances may mandate that 
surgical revision/ excision is carried out, for example in patients with false aneurysm 
formation or bleeding at the anastomosis, or patients who have developed arteriovenous or 
enteric fistulae. If removal of a vascular graft is deemed imperative, due to infection, then 
the surgical options are complex and include in situ graft replacement- using autogenous, 
prosthetic or impregnated grafts, or removal with extra-anatomic bypass.  
 
Cardiac 
In cases of pocket infection associated with intra-cardiac devices it may be possible to treat 
with antibiotics and simply drain any superficial collections, however leads have often 
already become colonised and therefore antibiotic treatment alone is rarely effective in 
preventing recurrence. For patients who are deemed fit the device can be removed and 
rhythm temporarily controlled using transvenous pacing wires or an external pacing vest. 
The new device is then placed on the contralateral side between 2 and 6 weeks later. 
Patients deemed to be unfit for such a procedure may need intermittent antibiotic therapy 
for the duration of their life. 
Infections of prosthetic heart valves have a mortality rate of around 30%. Surgical 
replacement of the valves can be performed only in specialist centres and is often only 
carried out if medical therapy has failed or is the patient is displaying cardiovascular or 
cerebrovascular complications.  
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Current research and developments 
 
New prostheses are being developed to employ the same principles as antimicrobial coated 
sutures. Neurosurgical shunts impregnated with antibiotic agents have been shown to be 
clinically and cost effective in reducing infective morbidity and mortality[21].  In orthopaedic 
practice antimicrobial or antibiotic coated implants and antibiotic bonded cement have 
shown promising results in combination with systemic antibiotics, in animal models and 
early human trials in prevention of implant associated infections[22, 23]. Early trials in 
antimicrobial coating of hernia mesh implants have been reported [24] as well as coating of 
vascular grafts with Triclosan and Rifampicin resulting in significantly reduced microbial load 
and rate of surgical site infections in animal models[25].  
 
Concerns have been raised that antibiotic bonding may lead to an increased level of 
pathogen resistance and work is also underway to create new biological prostheses, which 
provoke no foreign body reaction thus negating the need for prophylactic antimicrobial 
impregnation or coatings.  In vascular surgery biosynthetic devices composed of ovine 
collagen grown around a polyester mesh template have shown promising medium term 
results for revision implant surgery with implantation into infected surgical fields[26]. Early 
human studies are also underway using grafts grown in-vitro from banked human derived 
vascular smooth muscle cells which are then de-cellularised to eliminate risk of host 
rejection following implantation. Results of phase 1 trials are awaited.   
 
Biological meshes have been widely used for several years particularly for repair of 
abdominal wall defects. These are comprised of acellular extracts obtained from either 
human or non-human, usually porcine, sources. Significantly higher costs means their use is 
typically reserved for use in contaminated or dirty wounds though this use is unlicensed and 
there is a paucity of evidence to support this use[27].   
 
Conclusion 
Prosthetic implant infections result in significant morbidity and mortality for patients and 
huge costs to healthcare systems. Due to the serious implications it is imperative that all 
appropriate preventative measures against SSI and implant infection are employed. 
Surgeons must work closely with other healthcare professionals to optimise patient, 
surgical, anaesthetic and environmental risk factors. Newer antimicrobial or biological 
implants may also help to reduce the incidence of this devastating complication. 
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